The 3 papers in this issue on Helicobacter hepaticus infections in mice illustrate an emerging disease and new issue for mouse toxicology and carcinogenesis bioassays.
This new virulent bacterium was first described in NCI experimental A/JCr mice at Frederick, Maryland. Subsequently, NTP pathologists identified it as a confounding factor in 9 contract bioassays with B6C3F] mice. Dr. Fox I and his colleagues characterized the organism. He and others have now found widespread infection in American mouse production and research colonies. The hepatitis caused by H. hepaticus occurs more commonly and severely in male mice of some strains and stocks including A/J, BALB/c, C3H, B6C3F, and CD-1 mice. After 1 yr of age, these infected mice can develop high incidences of liver tumors. The hepatitis is associated with changes in levels of hepatocyte cell proliferation, metabolism, and gene expression. In addition, all mice have large bowel infection that may be associated with inflammation, changes in gastrointestinal flora and other parameters. All these factors may play a role in the responses of the mice to xenobiotics used in toxicology and carcinogenesis bioassays. Unfortunately, at present, at least 5 Helicobacter species have been isolated from mice; H. hepaticus appears to be the most virulent. This organism and other Helicobacter species also cause chronic large bowel disease in mice and can be associated with colon tumorigenesis in some types of knockout mice. It is imperative that mice used in safety assessment studies be free of all Helicobacter species. 
